Shopping Cart 0
Cart Subtotal
AED 0

Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 19708

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 33012

Details

According to a new report published by Allied Market Research, titled,"Head & Neck Cancer Drugs Market by Drug Class and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global head & neck cancer drugs market was valued at USD 1,295 million in 2017, and is expected to reach USD 2,281 million by 2025, growing at a CAGR of 7.3% from 2018 to 2025.

Head & neck cancer drugs include chemotherapy and targeted & immune therapeutic drugs, which are used alone or in combination for treatment of throat, larynx, nose, sinuses, lips, salivary glands, and mouth cancers. It is estimated that head & neck cancer drugs market is expected to exhibit significant market growth over the forecast period due to growth in number of target population, rise in demand for combination therapy, advancement in screening & diagnosis procedures, and expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, and Bevacizumab.

Based on drug class, the global head & neck cancer drugs market is categorized as chemotherapy agents, immunotherapy, and targeted therapy. Chemotherapy was the major revenue contributing segment in 2017, due to increase in adoption of chemotherapeutics for treatment of head & neck cancer along with radiation therapy and rise in demand for combination therapy. However, the market for immune therapeutic drugs is projected to exhibit the fastest market growth during the forecast period owing to strong presence of pipeline drugs, rise in usage of Yervoy & Keytruda along with the supportive reimbursement policies for usage of immunotherapy drugs in some countries.

According to sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. Currently, drug stores & retail pharmacies segment is major revenue contributor due to massive presence of these pharmacies. However, online providers segment is expected to show fastest market growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users.

Key Findings of the Head & Neck Cancer Drugs Market:

Based on sales channel, the online stores segment is expected to experience fastest market and is projected to grow at a CAGR of 10.2% during the forecast period 2018-2025.

Depending on drug class, the chemotherapy segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 4.0% from 2018 to 2025.

Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.7% during the forecast period.

North America accounted for nearly one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This was attributed to higher demand for head & neck cancer drugs, higher number target population, favorable reimbursement policies in healthcare system, increase in number of trained medical professionals with wide availability of the advance therapeutics. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of head & neck cancer, upsurge in demand for head & neck cancer drugs with improvement in healthcare infrastructure.

READ MORE

Table Of Content

Scope

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top player positioning

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Surge in incidence of head and neck cancer worldwide

3.3.1.2. Surge in global geriatric population

3.3.1.3. Increase in consumption of tobacco and alcohol

3.3.2. Restraints

3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs

3.3.3. Opportunities

3.3.3.1. Untapped emerging economies

3.3.3.2. Increase in number of pipeline drugs

3.3.4. Impact Analyses

CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast

4.2.3. Market analysis, by country

4.3. Immunotherapy

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast

4.3.3. Market analysis, by country

4.4. Targeted therapy

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast

4.4.3. Market analysis, by country

CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospital pharmacy

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

5.3. Online providers

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Drug stores & retail pharmacies

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class

6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel

6.2.2.2. Canada

6.2.2.2.1. Canada head & neck cancer drugs market, by drug class

6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class

6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel

6.2.3. North America market size and forecast, by drug class

6.2.4. North America market size and forecast, by sales channel

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany head & neck cancer drugs market, by drug class

6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel

6.3.2.2. France

6.3.2.2.1. France head & neck cancer drugs market, by drug class

6.3.2.2.2. France head & neck cancer drugs market, by sales channel

6.3.2.3. UK

6.3.2.3.1. UK head & neck cancer drugs market, by drug class

6.3.2.3.2. UK head & neck cancer drugs market, by sales channel

6.3.2.4. Italy

6.3.2.4.1. Italy head & neck cancer drugs market, by drug class

6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel

6.3.2.5. Spain

6.3.2.5.1. Spain head & neck cancer drugs market, by drug class

6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class

6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel

6.3.3. Europe market size and forecast, by drug class

6.3.4. Europe market size and forecast, by sales channel

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan head & neck cancer drugs market, by drug class

6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel

6.4.2.2. China

6.4.2.2.1. China head & neck cancer drugs market, by drug class

6.4.2.2.2. China head & neck cancer drugs market, by sales channel

6.4.2.3. Australia

6.4.2.3.1. Australia head & neck cancer drugs market, by drug class

6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel

6.4.2.4. India

6.4.2.4.1. India head & neck cancer drugs market, by drug class

6.4.2.4.2. India head & neck cancer drugs market, by sales channel

6.4.2.5. South Korea

6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class

6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class

6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel

6.4.3. Asia-Pacific market size and forecast, by type

6.4.4. Asia-Pacific market size and forecast, by sales channel

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class

6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class

6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel

6.5.2.3. South Africa

6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class

6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class

6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel

6.5.3. LAMEA market size and forecast, by type

6.5.4. LAMEA market size and forecast, by sales channel

CHAPTER 7: COMPANY PROFILES

7.1. AstraZeneca Plc.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

7.2. Bristol-Myers Squibb Company

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. Eli Lilly and Company

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.5. Fresenius Medical Care AG & Co. KGaA

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product Portfolio

7.5.5. Business performance

7.6. Merck & Co., Inc.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product Portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. Pfizer Inc.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

7.8. Sanofi

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

7.9. Sun Pharmaceutical Industries Ltd.

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

7.10. Teva Pharmaceutical Industries Limited

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

7.10.6.Key strategic moves and developments


List Of Figure

LIST OF FIGURES

FIGURE 01. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL HEAD & NECK CANCER DRUGS MARKET

FIGURE 03. TOP PLAYER POSITIONING, 2017

FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)

FIGURE 05. IMPACT ANALYSES, HEAD AND NECK CANCER DRUG MARKET

FIGURE 06. COMPARATIVE COUNTRY ANALYSIS OF CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 07. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 08. COMPARATIVE COUNTRY ANALYSIS OF TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 09. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 (USD MILLION)

FIGURE 10. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 (USD MILLION)

FIGURE 11. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 (USD MILLION)

FIGURE 12. ASTRAZENECA: REVENUE, 20152017 (USD MILLION)

FIGURE 13. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 14. REVENUE, 20152017 (USD MILLION)

FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 16. REVENUE, 20152017 (USD MILLION)

FIGURE 17. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 18. LILLY: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 19. ROCHE: NET SALES, 20152017 (USD MILLION)

FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 22. FRESENIUS MEDICAL CARE: NET SALES, 20152017 (USD MILLION)

FIGURE 23. FRESENIUS MEDICAL CARE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 24. MERCK: NET SALES, 20152017 (USD MILLION)

FIGURE 25. MERCK: NET SALES BY SEGMENT, 2017 (%)

FIGURE 26. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)

FIGURE 27. PFIZER: REVENUE, 20152017 (USD MILLION)

FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 30. SANOFI: NET SALES, 20152017 (USD MILLION)

FIGURE 31. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 32. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 33. SUN PHARMA: NET SALES, 20152017 (USD MILLION)

FIGURE 34. SUN PHARMA: NET SALES BY SEGMENT, 2017 (%)

FIGURE 35. TEVA: REVENUE, 20152017 (USD MILLION)

FIGURE 36. TEVA: REVENUE BY SEGMENT, 2017 (%)

FIGURE 37. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

TABLE 01. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 02. CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 03. IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 04. TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 05. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 06. HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 20172025 (USD MILLION)

TABLE 07. HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 20172025 (USD MILLION)

TABLE 08. HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 20172025 (USD MILLION)

TABLE 09. HEAD & NECK CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 10. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 11. U.S. HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 12. U.S. HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 13. CANADA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 14. CANADA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 15. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 16. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 17. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 18. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 19. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 20. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 21. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 22. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 23. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 24. UK HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 25. UK HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 26. ITALY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 27. ITALY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 28. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 29. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 30. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 31. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 32. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 33. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 34. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 35. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 36. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 37. CHINA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 38. CHINA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 39. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 40. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 41. INDIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 42. INDIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 43. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 44. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 45. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 46. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 47. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 49. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 50. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 51. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 52. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 53. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 54. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 55. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 56. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 57. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 58. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 59. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 60. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 61. ASTRAZENECA: OPERATING SEGMENTS

TABLE 62. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 63. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 64. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 65. LILLY: COMPANY SNAPSHOT

TABLE 66. LILLY: OPERATING SEGMENTS

TABLE 67. LILLY: PRODUCT PORTFOLIO

TABLE 68. ROCHE: COMPANY SNAPSHOT

TABLE 69. ROCHE: OPERATING SEGMENTS

TABLE 70. ROCHE: PRODUCT PORTFOLIO

TABLE 71. FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT

TABLE 72. FRESENIUS MEDICAL CARE: OPERATING SEGMENTS

TABLE 73. FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO

TABLE 74. MERCK: COMPANY SNAPSHOT

TABLE 75. MERCK: OPERATING SEGMENTS

TABLE 76. MERCK: PRODUCT PORTFOLIO

TABLE 77. PFIZER: COMPANY SNAPSHOT

TABLE 78. PFIZER: OPERATING SEGMENTS

TABLE 79. PFIZER: PRODUCT PORTFOLIO

TABLE 80. SANOFI: COMPANY SNAPSHOT

TABLE 81. SANOFI: OPERATING SEGMENTS

TABLE 82. SANOFI: PRODUCT PORTFOLIO

TABLE 83. SUN PHARMA: COMPANY SNAPSHOT

TABLE 84. SUN PHARMA: OPERATING SEGMENTS

TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 86. TEVA: COMPANY SNAPSHOT

TABLE 87. TEVA: OPERATING SEGMENTS

TABLE 88. TEVA: PRODUCT PORTFOLIO

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

According to a new report published by Allied Market Research, titled,"Head & Neck Cancer Drugs Market by Drug Class and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global head & neck cancer drugs market was valued at USD 1,295 million in 2017, and is expected to reach USD 2,281 million by 2025, growing at a CAGR of 7.3% from 2018 to 2025.

Head & neck cancer drugs include chemotherapy and targeted & immune therapeutic drugs, which are used alone or in combination for treatment of throat, larynx, nose, sinuses, lips, salivary glands, and mouth cancers. It is estimated that head & neck cancer drugs market is expected to exhibit significant market growth over the forecast period due to growth in number of target population, rise in demand for combination therapy, advancement in screening & diagnosis procedures, and expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, and Bevacizumab.

Based on drug class, the global head & neck cancer drugs market is categorized as chemotherapy agents, immunotherapy, and targeted therapy. Chemotherapy was the major revenue contributing segment in 2017, due to increase in adoption of chemotherapeutics for treatment of head & neck cancer along with radiation therapy and rise in demand for combination therapy. However, the market for immune therapeutic drugs is projected to exhibit the fastest market growth during the forecast period owing to strong presence of pipeline drugs, rise in usage of Yervoy & Keytruda along with the supportive reimbursement policies for usage of immunotherapy drugs in some countries.

According to sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. Currently, drug stores & retail pharmacies segment is major revenue contributor due to massive presence of these pharmacies. However, online providers segment is expected to show fastest market growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users.

Key Findings of the Head & Neck Cancer Drugs Market:

Based on sales channel, the online stores segment is expected to experience fastest market and is projected to grow at a CAGR of 10.2% during the forecast period 2018-2025.

Depending on drug class, the chemotherapy segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 4.0% from 2018 to 2025.

Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.7% during the forecast period.

North America accounted for nearly one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This was attributed to higher demand for head & neck cancer drugs, higher number target population, favorable reimbursement policies in healthcare system, increase in number of trained medical professionals with wide availability of the advance therapeutics. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of head & neck cancer, upsurge in demand for head & neck cancer drugs with improvement in healthcare infrastructure.

READ MORE

Scope

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top player positioning

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Surge in incidence of head and neck cancer worldwide

3.3.1.2. Surge in global geriatric population

3.3.1.3. Increase in consumption of tobacco and alcohol

3.3.2. Restraints

3.3.2.1. Adverse effects associated with the use of head and neck cancer drugs

3.3.3. Opportunities

3.3.3.1. Untapped emerging economies

3.3.3.2. Increase in number of pipeline drugs

3.3.4. Impact Analyses

CHAPTER 4: HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast

4.2.3. Market analysis, by country

4.3. Immunotherapy

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast

4.3.3. Market analysis, by country

4.4. Targeted therapy

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast

4.4.3. Market analysis, by country

CHAPTER 5: HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospital pharmacy

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

5.3. Online providers

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Drug stores & retail pharmacies

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

CHAPTER 6: HEAD & NECK CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. head & neck cancer drugs market, by drug class

6.2.2.1.2. U.S. head & neck cancer drugs market, by sales channel

6.2.2.2. Canada

6.2.2.2.1. Canada head & neck cancer drugs market, by drug class

6.2.2.2.2. Canada head & neck cancer drugs market, by sales channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico head & neck cancer drugs market, by drug class

6.2.2.3.2. Mexico head & neck cancer drugs market, by sales channel

6.2.3. North America market size and forecast, by drug class

6.2.4. North America market size and forecast, by sales channel

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany head & neck cancer drugs market, by drug class

6.3.2.1.2. Germany head & neck cancer drugs market, by sales channel

6.3.2.2. France

6.3.2.2.1. France head & neck cancer drugs market, by drug class

6.3.2.2.2. France head & neck cancer drugs market, by sales channel

6.3.2.3. UK

6.3.2.3.1. UK head & neck cancer drugs market, by drug class

6.3.2.3.2. UK head & neck cancer drugs market, by sales channel

6.3.2.4. Italy

6.3.2.4.1. Italy head & neck cancer drugs market, by drug class

6.3.2.4.2. Italy head & neck cancer drugs market, by sales channel

6.3.2.5. Spain

6.3.2.5.1. Spain head & neck cancer drugs market, by drug class

6.3.2.5.2. Spain head & neck cancer drugs market, by sales channel

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe head & neck cancer drugs market, by drug class

6.3.2.6.2. Rest of Europe head & neck cancer drugs market, by sales channel

6.3.3. Europe market size and forecast, by drug class

6.3.4. Europe market size and forecast, by sales channel

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan head & neck cancer drugs market, by drug class

6.4.2.1.2. Japan head & neck cancer drugs market, by sales channel

6.4.2.2. China

6.4.2.2.1. China head & neck cancer drugs market, by drug class

6.4.2.2.2. China head & neck cancer drugs market, by sales channel

6.4.2.3. Australia

6.4.2.3.1. Australia head & neck cancer drugs market, by drug class

6.4.2.3.2. Australia head & neck cancer drugs market, by sales channel

6.4.2.4. India

6.4.2.4.1. India head & neck cancer drugs market, by drug class

6.4.2.4.2. India head & neck cancer drugs market, by sales channel

6.4.2.5. South Korea

6.4.2.5.1. South Korea head & neck cancer drugs market, by drug class

6.4.2.5.2. South Korea head & neck cancer drugs market, by sales channel

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific head & neck cancer drugs market, by drug class

6.4.2.6.2. Rest of Asia-Pacific head & neck cancer drugs market, by sales channel

6.4.3. Asia-Pacific market size and forecast, by type

6.4.4. Asia-Pacific market size and forecast, by sales channel

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil head & neck cancer drugs market, by drug class

6.5.2.1.2. Brazil head & neck cancer drugs market, by sales channel

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia head & neck cancer drugs market, by drug class

6.5.2.2.2. Saudi Arabia head & neck cancer drugs market, by sales channel

6.5.2.3. South Africa

6.5.2.3.1. South Africa head & neck cancer drugs market, by drug class

6.5.2.3.2. South Africa head & neck cancer drugs market, by sales channel

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA head & neck cancer drugs market, by drug class

6.5.2.4.2. Rest of LAMEA head & neck cancer drugs market, by sales channel

6.5.3. LAMEA market size and forecast, by type

6.5.4. LAMEA market size and forecast, by sales channel

CHAPTER 7: COMPANY PROFILES

7.1. AstraZeneca Plc.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

7.2. Bristol-Myers Squibb Company

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. Eli Lilly and Company

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

7.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.5. Fresenius Medical Care AG & Co. KGaA

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product Portfolio

7.5.5. Business performance

7.6. Merck & Co., Inc.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product Portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. Pfizer Inc.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

7.8. Sanofi

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

7.9. Sun Pharmaceutical Industries Ltd.

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

7.10. Teva Pharmaceutical Industries Limited

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

7.10.6.Key strategic moves and developments


List Of Figure

LIST OF FIGURES

FIGURE 01. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL HEAD & NECK CANCER DRUGS MARKET

FIGURE 03. TOP PLAYER POSITIONING, 2017

FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)

FIGURE 05. IMPACT ANALYSES, HEAD AND NECK CANCER DRUG MARKET

FIGURE 06. COMPARATIVE COUNTRY ANALYSIS OF CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 07. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 08. COMPARATIVE COUNTRY ANALYSIS OF TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 (USD MILLION)

FIGURE 09. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 (USD MILLION)

FIGURE 10. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 (USD MILLION)

FIGURE 11. COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 (USD MILLION)

FIGURE 12. ASTRAZENECA: REVENUE, 20152017 (USD MILLION)

FIGURE 13. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 14. REVENUE, 20152017 (USD MILLION)

FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 16. REVENUE, 20152017 (USD MILLION)

FIGURE 17. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 18. LILLY: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 19. ROCHE: NET SALES, 20152017 (USD MILLION)

FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 22. FRESENIUS MEDICAL CARE: NET SALES, 20152017 (USD MILLION)

FIGURE 23. FRESENIUS MEDICAL CARE: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 24. MERCK: NET SALES, 20152017 (USD MILLION)

FIGURE 25. MERCK: NET SALES BY SEGMENT, 2017 (%)

FIGURE 26. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)

FIGURE 27. PFIZER: REVENUE, 20152017 (USD MILLION)

FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 30. SANOFI: NET SALES, 20152017 (USD MILLION)

FIGURE 31. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 32. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 33. SUN PHARMA: NET SALES, 20152017 (USD MILLION)

FIGURE 34. SUN PHARMA: NET SALES BY SEGMENT, 2017 (%)

FIGURE 35. TEVA: REVENUE, 20152017 (USD MILLION)

FIGURE 36. TEVA: REVENUE BY SEGMENT, 2017 (%)

FIGURE 37. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

TABLE 01. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 02. CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 03. IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 04. TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20172025 (USD MILLION)

TABLE 05. GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 06. HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 20172025 (USD MILLION)

TABLE 07. HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 20172025 (USD MILLION)

TABLE 08. HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 20172025 (USD MILLION)

TABLE 09. HEAD & NECK CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 10. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 11. U.S. HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 12. U.S. HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 13. CANADA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 14. CANADA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 15. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 16. MEXICO HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 17. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 18. NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 19. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 20. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 21. GERMANY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 22. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 23. FRANCE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 24. UK HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 25. UK HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 26. ITALY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 27. ITALY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 28. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 29. SPAIN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 30. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 31. REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 32. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 33. EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 34. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 35. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 36. JAPAN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 37. CHINA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 38. CHINA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 39. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 40. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 41. INDIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 42. INDIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 43. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 44. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 45. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 46. REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 47. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 48. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 49. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 50. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 51. BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 52. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 53. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 54. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 55. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 56. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 57. REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 58. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 20172025 (USD MILLION)

TABLE 59. LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 20172025 (USD MILLION)

TABLE 60. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 61. ASTRAZENECA: OPERATING SEGMENTS

TABLE 62. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 63. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 64. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 65. LILLY: COMPANY SNAPSHOT

TABLE 66. LILLY: OPERATING SEGMENTS

TABLE 67. LILLY: PRODUCT PORTFOLIO

TABLE 68. ROCHE: COMPANY SNAPSHOT

TABLE 69. ROCHE: OPERATING SEGMENTS

TABLE 70. ROCHE: PRODUCT PORTFOLIO

TABLE 71. FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT

TABLE 72. FRESENIUS MEDICAL CARE: OPERATING SEGMENTS

TABLE 73. FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO

TABLE 74. MERCK: COMPANY SNAPSHOT

TABLE 75. MERCK: OPERATING SEGMENTS

TABLE 76. MERCK: PRODUCT PORTFOLIO

TABLE 77. PFIZER: COMPANY SNAPSHOT

TABLE 78. PFIZER: OPERATING SEGMENTS

TABLE 79. PFIZER: PRODUCT PORTFOLIO

TABLE 80. SANOFI: COMPANY SNAPSHOT

TABLE 81. SANOFI: OPERATING SEGMENTS

TABLE 82. SANOFI: PRODUCT PORTFOLIO

TABLE 83. SUN PHARMA: COMPANY SNAPSHOT

TABLE 84. SUN PHARMA: OPERATING SEGMENTS

TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 86. TEVA: COMPANY SNAPSHOT

TABLE 87. TEVA: OPERATING SEGMENTS

TABLE 88. TEVA: PRODUCT PORTFOLIO

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS